Back to search results

Reducing Vancomycin Use in Pediatric Sepsis

This study aims to reduce the overuse of vancomycin, an antibiotic, in children admitted to Pediatric Intensive Care Units (PICUs) with suspected sepsis (a severe response to infection). Too much vancomycin can cause kidney problems. Researchers will provide doctors and other healthcare staff with new guidelines on when to use vancomycin, give them feedback on how much vancomycin is being used, and offer education. The goal is to see if these changes can lower the overall use of vancomycin over five years. The study involves healthcare providers and patients admitted to participating PICUs. The current status of the study is unclear.

Study design
This is an interventional study involving two groups: PICU clinicians/sepsis stakeholders and patients admitted to participating PICUs. It plans to enroll 52,500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Changes in vancomycin use will be measured from the start of the study up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05975671

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

Recruiting
NAAll AgesInterventional
Children's Hospital of Philadelphia
~52,500 participants
Updated 2025-09-19 on ClinicalTrials.gov
What's tested:Multifaceted de-implementation strategy to reduce vancomycin overuse

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in vancomycin use
Measured over Baseline to 5 years

Conditions

Sepsis
Sepsis Mrsa
Sepsis Bacteremia
Antimicrobial - Induced Nephropathy
Sepsis, Severe
Septic Shock
Septic Syndrome

Explore related trials

Septicemia

Where it's being run

4 sites across 4 states
Georgia1
Maryland1
Missouri1
Pennsylvania1

Study leadership

  • Kathleen Chiotos, MD, MSCE · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia

Who to contact

Kathleen Chiotos, MD, MSCE
[email protected]
215-590-5505
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Admitted to one of the participating PICUs during the study period

Exclusion

None

What this trial measures

  • Change in vancomycin useBaseline to 5 years

    Vancomycin use will be measured as DOT per 1000 PICU patient days, measured monthly. Every day in which one or more doses of parenteral vancomycin is administered is classified as one vancomycin DOT. Every day or portion of a day a patient is admitted to the PICU is classified as one PICU patient day.